journal
MENU ▼
Read by QxMD icon Read
search

Cancer Journal

journal
https://www.readbyqxmd.com/read/28114259/challenges-in-conducting-clinical-research-on-patients-with-advanced-melanoma
#1
Mario Sznol
Unprecedented advances in the treatment of melanoma and the large number of investigational therapies entering clinical studies not only represent outstanding achievements, but also create major challenges for clinical research in melanoma. The challenges for accrual and for developing important new data in trials include the relatively low incidence of melanoma compared with other diseases, a shrinking pool of patients for trials because of the high efficacy of standard of care therapy, requirements for larger studies and longer duration of follow-up to detect signals of activity or establish efficacy, and suboptimal predictive biomarkers for the vast number of new combinations and new agents...
January 2017: Cancer Journal
https://www.readbyqxmd.com/read/28114258/melanoma-brain-metastases-current-areas-of-investigation-and-future-directions
#2
Isabella Glitza Oliva, Hussein Tawbi, Michael A Davies
Metastases to the central nervous system (CNS) are one of the most common and lethal complications of metastatic melanoma. Historically, melanoma patients with CNS metastases have had dismal outcomes and very limited treatment options. However, the development of more effective targeted, immune, and radiation therapies is now leading to promising new investigations and strategies. Optimizing the development and testing of such strategies will benefit from an improved understanding of the unique molecular features of these tumors and the influence of the brain microenvironment...
January 2017: Cancer Journal
https://www.readbyqxmd.com/read/28114257/clinical-trial-design-and-endpoints-for-stage-iv-melanoma-in-the-modern-era
#3
Benjamin Izar, Meredith M Regan, David F McDermott
Immunotherapies and targeted therapies for the treatment of metastatic or advanced melanoma produce unique patterns of antitumor response. Conventional outcome measures, such as median progression-free and overall survival, may not be ideally suited to identify all patients who derive a benefit from such therapies. Therefore, the introduction of additional endpoint measures, such as milestone comparisons, may be necessary to characterize the potential benefit of such treatment approaches. Immune checkpoint inhibitors induce durable responses in a portion of patients that may continue after treatment cessation...
January 2017: Cancer Journal
https://www.readbyqxmd.com/read/28114256/targeted-therapies-in-combination-with-immune-therapies-for-the-treatment-of-metastatic-melanoma
#4
Shelly A Christiansen, Shaheer Khan, Geoffrey T Gibney
In recent years, the field of oncology has witnessed many breakthroughs in the treatment of advanced malignancies, particularly in patients with advanced melanoma. Targeted and immune checkpoint therapies have emerged as the primary treatment strategies for these patients. Molecular profiling of melanoma is incorporated into routine practice to identify potential therapeutic targets, and patients are offered either a targeted or immune checkpoint inhibitor therapy approach. Both strategies have limitations where not all patients experience durable responses...
January 2017: Cancer Journal
https://www.readbyqxmd.com/read/28114255/novel-targeted-therapies-for-metastatic-melanoma
#5
Wade T Iams, Jeffrey A Sosman, Sunandana Chandra
Oncogene-targeted therapy is a major component of precision oncology, and although patients with metastatic melanoma have experienced improved outcomes with this strategy, there are a number of potential therapeutic targets currently under study that may further increase the drug armamentarium for this patient population. In this review, we discuss the landscape of targeted therapies for patients with advanced melanoma, focusing on oncogene mutation-specific targets. In patients with typical BRAF V600-mutant melanoma, combination BRAF and MEK inhibition has surpassed outcomes compared with monotherapy with BRAF or MEK inhibition alone, and current strategies seek to address inevitable resistance mechanisms...
January 2017: Cancer Journal
https://www.readbyqxmd.com/read/28114254/adoptive-cell-therapy-for-metastatic-melanoma
#6
Efrat Merhavi-Shoham, Orit Itzhaki, Gal Markel, Jacob Schachter, Michal J Besser
Adoptive cell therapy (ACT) of tumor-infiltrating lymphocytes (TILs) is a powerful form of immunotherapy by inducing durable complete responses that significantly extend the survival of melanoma patients. Mutation-derived neoantigens were recently identified as key factors for tumor recognition and rejection by TILs. The isolation of T-cell receptor (TCR) genes directed against neoantigens and their retransduction into peripheral T cells may provide a new form of ACT.Genetic modifications of T cells with chimeric antigen receptors (CARs) have demonstrated remarkable clinical results in hematologic malignancies, but are so far less effective in solid tumors...
January 2017: Cancer Journal
https://www.readbyqxmd.com/read/28114253/intratumoral-approaches-for-the-treatment-of-melanoma
#7
Praveen K Bommareddy, Ann W Silk, Howard L Kaufman
There have been significant advances in the immunotherapy of melanoma over the last decade. The tumor microenvironment is now known to promote an immune-suppressive milieu that can block effective immune-mediated tumor rejection. Several novel strategies designed to overcome local immunosuppression hold promise for treatment of melanoma and other cancers. These approaches include oncolytic viruses, plasmid DNA delivery, Toll-like receptor agonists, inflammatory dyes, cytokines, checkpoint inhibitors, immunomodulatory agents, and host and pathogenic cell-based vectors...
January 2017: Cancer Journal
https://www.readbyqxmd.com/read/28114252/radiotherapy-and-immune-checkpoint-blockade-for-melanoma-a-promising-combinatorial-strategy-in-need-of-further-investigation
#8
Freddy E Escorcia, Michael A Postow, Christopher A Barker
Radiotherapy and immune checkpoint blockade are effective treatments for melanoma. Recent preclinical studies have suggested an interaction of radiotherapy and immune checkpoint blockade. Retrospective clinical studies, as well as a small number of prospective studies, have been undertaken to explore this interaction in patients with melanoma. In this review, we present the results of clinical studies combining radiotherapy and immune checkpoint blockade and conclude that this is a promising strategy worth of further investigation...
January 2017: Cancer Journal
https://www.readbyqxmd.com/read/28114251/novel-checkpoints-and-cosignaling-molecules-in-cancer-immunotherapy
#9
Iulia Giuroiu, Jeffrey Weber
The recent demonstration of the antitumor efficacy of checkpoint protein inhibition has resulted in the approval of blocking antibodies against the programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) pathway in multiple different histologic findings. Therapeutic successes with PD-1/PD-L1 antibodies in melanoma and lung cancer have been followed by approvals in bladder, renal, and head and neck cancers and Hodgkin lymphoma, with others undoubtedly to come. However, PD-1 is only one of many checkpoints and agonistic regulatory molecules expressed on T cells by which maintenance of the balance between costimulatory and coinhibitory signaling pathways is perturbed in cancer...
January 2017: Cancer Journal
https://www.readbyqxmd.com/read/28114250/new-combination-strategies-using-programmed-cell-death-1-programmed-cell-death-ligand-1-checkpoint-inhibitors-as-a-backbone
#10
Siwen Hu-Lieskovan, Antoni Ribas
The discovery of immune checkpoints and subsequent clinical development of checkpoint inhibitors have revolutionized the field of oncology. The durability of the antitumor immune responses has raised the hope for long-term patient survival and potential cure; however, currently, only a minority of patients respond. Combination strategies to help increase antigen release and T-cell priming, promote T-cell activation and homing, and improve the tumor immune microenvironment, all guided by predictive biomarkers, can help overcome the tumor immune-evasive mechanisms and maximize efficacy to ultimately benefit the majority of patients...
January 2017: Cancer Journal
https://www.readbyqxmd.com/read/28114249/inhibitors-of-cytotoxic-t-lymphocyte-antigen-4-and-programmed-death-1-programmed-death-1-ligand-for-metastatic-melanoma-dual-versus-monotherapy-summary-of-advances-and-future-directions-for-studying-these-drugs
#11
Kimberly Loo, Adil I Daud
Immense progress in the field of cancer immunotherapy has garnered several novel and successful treatments for metastatic melanoma. Beginning with therapies targeting cytotoxic T lymphocyte antigen 4 (CTLA-4), objective response rates, overall survival, and long-term survival were significantly increased when compared with glycoprotein 100 vaccine therapies. Expanding the breadth of therapies aimed to "release the breaks" on the active immune system, anti-programmed death 1 (PD-1) and anti-programmed death 1 ligand (PD-L1) therapies further improved overall survival, progression-free survival, and objective tumor response while exhibiting more favorable safety profiles compared with ipilimumab and to chemotherapy agents...
January 2017: Cancer Journal
https://www.readbyqxmd.com/read/28114248/from-the-guest-editors-recent-advances-and-evolving-challenges-in-treating-unresectable-melanoma
#12
Sarah A Weiss, Harriet M Kluger
No abstract text is available yet for this article.
January 2017: Cancer Journal
https://www.readbyqxmd.com/read/27870686/era-of-a-single-population-based-payment-to-a-cancer-center-delivering-the-value-of-interventional-oncology-in-accountable-care-organizations
#13
Jemianne B Jia, Riccardo Lencioni, Howard P Forman, Hyun S Kim
To curtail increasing health care costs, the government has ushered in the era of the Accountable care organization (ACO). The purposes of this review are to evaluate the effects the ACO will have on the practice of interventional oncology and its role in cancer care and to explore methods to assimilate. Proposed action points include integration into the modern-day cancer center, adoption of an outpatient clinic, mandatory performance measures, and workflow and cost analysis. If adaptations are made, interventional oncology can continue its role in cancer treatment, will provide more effective care, and reach more patients in the new ACO...
November 2016: Cancer Journal
https://www.readbyqxmd.com/read/27870685/the-importance-of-biopsy-in-the-era-of-molecular-medicine
#14
Etay Ziv, Jeremy C Durack, Stephen B Solomon
Recent advances in the molecular characterization of cancers have triggered interest in developing a new taxonomy of disease in oncology with the goal of using the molecular profile of a patient's tumor to predict response to treatment. Image-guided needle biopsy is central to this "precision medicine" effort. In this review, we first discuss the current role of biopsy in relation to clinical examples of molecular medicine. We then outline important bottlenecks to the advancement of precision medicine and highlight the potential role of image-guided biopsy to address these challenges...
November 2016: Cancer Journal
https://www.readbyqxmd.com/read/27870684/palliative-interventional-oncology
#15
Alexandra H Fairchild, William S Rilling
Interventional oncologists are playing an ever greater role in improving the quality of life of their patients through minimally invasive procedures, many of which can be performed on an outpatient basis. Some of the most common palliative procedures currently performed will be discussed including management of intractable ascites and pleural effusions, neurolytic plexus blocks, and palliation of pain and bleeding associated with metastatic tumors.
November 2016: Cancer Journal
https://www.readbyqxmd.com/read/27870683/increasing-role-of-image-guided-ablation-in-the-treatment-of-musculoskeletal-tumors
#16
Anil Nicholas Kurup, Matthew R Callstrom
In the last decade, percutaneous treatment of musculoskeletal (MSK) tumors has become more established in routine clinical care while also undergoing a number of advancements. Ablative techniques to palliate painful skeletal metastases have gained wide acceptance, while goals for ablation have evolved to include local control of oligometastases and desmoid tumors. Bone consolidation or augmentation is now frequently used in conjunction with or instead of ablation of skeletal tumors to stabilize pathologic fractures or prevent further morbidity that could result from fractures caused by tumor progression...
November 2016: Cancer Journal
https://www.readbyqxmd.com/read/27870682/advances-in-interventional-oncology-lung-cancer
#17
Philip J Dempsey, Carole A Ridge, Stephen B Solomon
Image-guided lung intervention in the oncologic patient includes transthoracic needle biopsy, thermal ablation, fiducial placement, and tunneled pleural catheter placement and is made possible by technical advancements in computed tomography, fluoroscopy, and ultrasound technology, as well as the proliferation of available thermal ablation modalities such as radiofrequency, microwave, and cryoablation. With increasingly earlier cancer diagnoses being made and a greater patient demand for minimally invasive therapies, interventional oncology has many options to offer the patient with thoracic malignancies...
November 2016: Cancer Journal
https://www.readbyqxmd.com/read/27870681/kidney-cancer
#18
S Brandon Hancock, Christos S Georgiades
The number of new cases of renal cell carcinoma has been steadily increasing since the 1960s, reaching 62,000 and 89,000 annually in the United States and Europe, respectively, in 2016. The current standard of care for early-stage disease is nephron-sparing surgery, which has a demonstrated long-term disease-free survival and an acceptable safety profile. Technical developments (thin, powerful probes and real-time image guidance systems) have allowed image-guided percutaneous ablation to become a viable option for stage I renal cell carcinoma...
November 2016: Cancer Journal
https://www.readbyqxmd.com/read/27870680/liver-metastases-from-noncolorectal-malignancies-neuroendocrine-tumor-sarcoma-melanoma-breast
#19
Erica S Alexander, Michael C Soulen
Patients with noncolorectal hepatic metastases often face limited treatment options and a dismal prognosis. Over the last decade, the advent of targeted immunotherapies has transformed the treatment of certain metastatic cancers, such as sarcoma and melanoma; however, these patients eventually develop resistance. Metastatic sarcoma, melanoma, and breast and neuroendocrine tumors are notoriously treatment resistant once they have metastasized to the liver. For these cancers, minimally invasive transarterial and ablation therapies have emerged as safe, palliative therapies that can provide symptom control and even prolong survival...
November 2016: Cancer Journal
https://www.readbyqxmd.com/read/27870679/new-developments-in-interventional-oncology-liver-metastases-from-colorectal-cancer
#20
Joseph R Kallini, Ahmed Gabr, Nadine Abouchaleh, Rehan Ali, Ahsun Riaz, Robert J Lewandowski, Riad Salem
Colorectal cancer is the third leading cause of cancer death in the United States. Although hepatic excision is the first-line treatment for colorectal liver metastasis (CRLM), few patients are candidates. Locoregional therapy (LRT) encompasses minimally invasive techniques practiced by interventional radiology. These include ablative treatments (radiofrequency ablation, microwave ablation, and cryosurgical ablation) and transcatheter intra-arterial therapy (hepatic arterial infusion chemotherapy, transarterial "bland" embolization, transarterial chemoembolization, and radioembolization with yttrium 90)...
November 2016: Cancer Journal
journal
journal
34932
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"